US stock research with a clear call, target price, and downside case.
Read public equity notes built around one useful question first: is this a BUY, HOLD, or SELL at today's price? Each note keeps the valuation, thesis, and risk case visible from the first screen.
Free alerts for new notes, requested-stock updates, and the next ticker you care about.
Free to join. Useful if you want quick research context before spending time on a company.
HON at $201.57
Honeywell International Inc. screens HOLD with a DCF-based target price of $201.57, versus a current price of $223.91 and modeled upside of -10%.
Why Investors Subscribe
The value proposition should be obvious fast: see the call, see the target, and get notified when new coverage or a requested stock goes live.
Read the setup quickly
Each note opens with the recommendation, target price, valuation anchor, and key financial context.
See the valuation clearly
DCF outputs, peer multiples, and sensitivity tables stay visible instead of buried in prose.
Track names you care about
Request coverage for a stock and get notified when that report is published.
Request Coverage
Missing a name you follow? Submit the ticker and join the coverage queue.
Coverage Queue
The names investors are asking us to cover next.
| Ticker | Requests | Latest |
|---|---|---|
| ASTS | 2 | 3/31/2026 |
| NIO | 1 | 4/2/2026 |
Recent Reports
Published notes stay available as structured, linkable pages.
HON
HOLDHoneywell International Inc. screens HOLD with a DCF-based target price of $201.57, versus a current price of $223.91 and modeled upside of -10%.
AVGO
SELLBroadcom Inc. screens SELL with a blended target price of $295.53, versus a current price of $396.72 and modeled upside of -25.5%.
COP
HOLDConocoPhillips screens HOLD with a blended target price of $148.06, versus a current price of $131.61 and modeled upside of 12.5%.
Inside Each Report
- Company snapshot and core thesis
- Business overview and financial analysis
- DCF valuation and sensitivity table
- Comparable valuation cross-check
- Clear recommendation and key risks
Stay Close to New Coverage
Join the list for free and get the next published report without having to check back manually.